The lymphedema treatment market size was valued at USD 840 million in 2021 and is projected to reach USD 1671 million by 2030, expanding at a CAGR of around 9% during the forecast period, 2022 – 2030. The growth of the market is attributed to the rising cases of cancer diseases.
When lymph fluids collect on the fatty tissues beneath the skin, it causes lymphedema. Malfunctioning of lymphatic system also causes lymphedema. It is a condition in which the lower and upper arms swell. Lymphedema is most usually induced by cancer treatment that involves the amputation or destruction of lymph nodes. It is caused by an obstruction in the immune system's lymphatic system. Infections, deformity, chronic pain, and incapacity can all result from a malfunctioning lymphatic system. Lymphoma does not have a cure. Because individuals are dissatisfied or do not get cured with traditional lymphedema treatment, numerous therapies are used instead of standard treatment. They go for an alternate treatment that gives them more influence over medical decisions and is much more suitable with the patient's health-care system.
Lymphedema can develop as a result of any cancer treatment that interferes with lymph node drainage. It has been known to happen days after breast cancer therapy and up to 30 years later. Therapies, procedures, and lymphovenous transplantation are among the first-line treatments for lymphedema.
The covid-19 pandemic severely affected the lymphedema treatment market. Academic and research institutes, as well as companies in the healthcare industry such as biochemicals, pharmaceuticals, and others, were badly impacted. Patients infected with the coronavirus were being treated in hospitals all around the world. As a result, people with various illnesses were adversely affected. Furthermore, the shutdown impacted the supply chain as well as the market.
Market Trends, Drivers, Restraints, and Opportunities
- Rising incidence of breast cancer and lymphedema disorders are projected to drive the market during the forecast period.
- The adoption of innovative lymphedema treatment products is estimated to fuel the market during the projected period.
- Government actions and policies to promote lymphedema treatment, as well as private investor funding is expected to have a positive impact on the market growth.
- Despite technical advances, there is no permanent treatment for lymphedema, which is anticipated to hinder the market growth.
- High cost associated with the treatment and surgeries is estimated to hamper the market growth.
- Increased spending on research, development, and healthcare is projected to offer immense opportunities for the market players during the forecast period.
Scope of Lymphedema Treatment Market Report
The report on the global lymphedema treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes
|
Details
|
Report Title
|
Lymphedema Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
Base Year
|
2021
|
Historic Data
|
2019–2020
|
Forecast Period
|
2022 – 2030
|
Segmentation
|
Types (Secondary Lymphedema and Primary Lymphedema), Treatment Types (Laser Therapy, Physiological Procedures, Drug Therapy, Surgery, Compression Therapy, and Others), Affected Areas (Genitalia, Upper Extremity, and Lower Extremity), Route of Administration (Injectable, Oral, and Others), End-users (Specialty Clinics, Ambulatory Surgical Centers, Hospitals, and Others)
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
Key Players Covered in the Report
|
Convatec; AIROS Medical Inc.; Avet Pharmaceuticals; Koya Medical; Huntleigh Healthcare Limited; Cardinal Health; 3M; Juzo; Lohmann & Rausher; Tactile Systems Technology Inc.; Wright Therapy Products; 3A Health Care; Herantis Pharma PLC; SIGVARIS; Bio Compression Systems Inc.; Mego Afek Ltd.; medi GmbH & Co. KG; KOYA MEDICAL; Avet Pharmaceuticals Inc.; and Tactile Medical
|
Lymphedema Treatment Market Segment Insights
Secondary lymphedema segment held major market share in 2021
Based on types, the market is segregated into secondary lymphedema and primary lymphedema. The secondary lymphedema segment accounted for a major market. Secondary lymphedema develops as a result of cancer treatment that damages the lymphatic system, such as radiation therapy or surgery. Primary lymphedema is caused by the formation of an aberrant lymph cluster. It usually occurs as a result of old age or birth.
Physiological procedures segment is anticipated to expand at a high CAGR during the forecast period
On the basis of treatment types, the market is fragmented into laser therapy, physiological procedures, drug therapy, surgery, compression therapy, and others. The physiological procedures segment is anticipated to expand at a high CAGR during the forecast period owing to the effective therapeutic approaches used on lymphedema patients, such as LVA and VLNT. These two treatments are effective therapy choices for patients with lymphedema.
Lower extremity segment is expected to hold major market share during the forecast period
In terms of affected areas, the market is divided into genitalia, upper extremity, and lower extremity. The lower extremity segment is expected to hold major market share during the forecast period as it is most commonly impacted part. Swelling of the ankles, legs, and feet is common in the lower extremity. One of the more complex disorders is upper extremity disease.
Oral segment dominated the market in 2021
Based on route of administration, the market is segregated into injectable, oral, and others. The oral segment dominated the market in 2021 because it is the most effective route of administration and has a higher level of patient compliance.
The hospitals segment accounted for a major market share in 2021
On the basis of end-users, the market is fragmented into, specialty clinics, ambulatory surgical centers, hospitals, and others. The hospitals segment accounted for a major market share in 2021. Growth of the market is attributed to launch of innovative technologies by the key players for allowing hospitals to make the most of their resources.
Asia Pacific is estimated to register a high CAGR during the forecast period
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. Asia Pacific is estimated to register a high CAGR during the forecast period owing to rising healthcare expenditure. Due to the country's expanding disposable income, China has dominated the Asia-Pacific market. China has dominated the Asia-Pacific market, due to the country's expanding disposable income.
Segments
The global lymphedema treatment market has been segmented on the basis of
Types
- Secondary Lymphedema
- Primary Lymphedema
Treatment Types
- Laser Therapy
- Physiological Procedures
- Drug Therapy
- Surgery
- Compression Therapy
- Others
Affected Areas
- Genitalia
- Upper Extremity
- Lower Extremity
Route of administration
End-users
- Specialty Clinics
- Ambulatory Surgical Centers
- Hospitals
- Others
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Convatec
- AIROS Medical Inc.
- Avet Pharmaceuticals
- Koya Medical
- Huntleigh Healthcare Limited
- Cardinal Health
- 3M
- Juzo
- Lohmann & Rausher
- Tactile Systems Technology Inc.
- Wright Therapy Products
- 3A Health Care
- Herantis Pharma PLC
- SIGVARIS
- Bio Compression Systems Inc.
- Mego Afek Ltd.
- medi GmbH & Co. KG
- KOYA MEDICAL
- Avet Pharmaceuticals Inc.
- Tactile Medical
Competitive Landscape
Key players competing in the lymphedema treatment market include Convatec; AIROS Medical Inc.; Avet Pharmaceuticals; Koya Medical; Huntleigh Healthcare Limited; Cardinal Health; 3M; Juzo; Lohmann & Rausher; Tactile Systems Technology Inc.; Wright Therapy Products; 3A Health Care; Herantis Pharma PLC; SIGVARIS; Bio Compression Systems Inc.; Mego Afek Ltd.; medi GmbH & Co. KG; KOYA MEDICAL; Avet Pharmaceuticals Inc.; and Tactile Medical. Some of these players are using several market strategies such as acquisitions, mergers, collaborations, partnerships, capacity expansion, and product launches to enhance their market share. For instance,
- In 2017, Tactile Systems Technology, Inc. introduced Flexitouch, the first pneumatic stimulation device for lymphedema treatment.
- In September 2020, Paul Hartmann announced a collaboration with Apollo Hospitals Group in West China and India, with an emphasis on wound care clinics and ambulances, as well as medical training.